SOURCE: Marina Biotech, Inc.

Marina Biotech, Inc.

April 12, 2011 08:30 ET

Marina Biotech Announces Patent Allowance for Its Proprietary Nucleic Acid Delivery Technology

Expands Global Patent Estate for SMARTICLES® Delivery Technology Currently in a Phase 1 Clinical Study for the Treatment of Cancer

BOTHELL, WA--(Marketwire - Apr 12, 2011) - Marina Biotech, Inc. (NASDAQ: MRNA), a leading RNAi-based drug discovery and development company, today announced that the Canadian Patent Office has issued a Notice of Allowance for patent application 2,438,116 with claims that broadly cover amphoteric liposomal formulations (SMARTICLES®) and their use for the delivery of nucleic acids and other compounds with therapeutic application. This allowance adds to the company's existing global patent estate for SMARTICLES delivery technology, which includes over 40 issued patents in countries including the United States, Japan, China, Singapore, Australia and countries throughout Europe.

At present, ProNAi Therapeutics Inc., a privately held biopharmaceutical company and licensee of the SMARTICLES technology, is conducting a dose-escalating Phase 1 clinical study with a novel cancer therapeutic candidate (PNT2258) formulated with Marina Biotech's patented SMARTICLES delivery technology. The primary objective of this study is to assess the safety and tolerability of PNT2258 in patients with advanced solid tumors, and to enable dose selection for subsequent efficacy studies in patients. A secondary objective of this study is pharmacokinetics. Thus far, ProNAi has enrolled six patients and completed dosing regimens on five of those patients.

"We are pleased that the Canadian patent office allowed these claims which cover and protect our SMARTICLES technology," stated J. Michael French, President and CEO at Marina Biotech. "The Company's global intellectual property portfolio represents fundamental IP necessary to develop and commercialize multiple RNA-based therapies. ProNAi's efforts demonstrate the breadth of that IP estate with the application of our delivery technology to their proprietary and innovative DNAi-based oligonucleotide molecule. Through ProNAi's efforts and capabilities, we expect to see significant SMARTICLES delivery technology advancements in the fight to treat cancer patients who have few, if any, therapeutic alternatives. In addition, we have ongoing collaborative efforts which are, in part, focused on both local and systemic delivery of siRNAs and other oligonucleotides using the SMARTICLES technology; one of multiple therapeutic options in the Marina Biotech nucleic acid-based discovery platform."

About Marina Biotech, Inc.

Marina Biotech is a biotechnology company, focused on the development and commercialization of RNA interference- (RNAi) and RNA-based therapeutics. The Marina Biotech pipeline currently includes a clinical program in Familial Adenomatous Polyposis (a precancerous syndrome) and two preclinical programs -- in hepatocellular carcinoma and bladder cancer. Marina Biotech has recently entered an exclusive agreement with Debiopharm Group for the development and commercialization of the bladder cancer program. Marina Biotech's goal is to improve human health through the development of RNAi and RNA-based compounds and drug delivery technologies that together provide superior therapeutic options for patients. Marina Biotech's global intellectual property portfolio includes 71 issued or allowed patents; 54 U.S. patent applications; 135 foreign patent applications; and 5 PCT applications providing broad coverage for siRNAs, chemistry, delivery and gene targets. Additional information about Marina Biotech is available at

Forward-Looking Statements

Statements made in this news release may be forward-looking statements within the meaning of Federal Securities laws that are subject to certain risks and uncertainties and involve factors that may cause actual results to differ materially from those projected or suggested. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to: (i) the ability of Marina Biotech to obtain additional funding; (ii) the ability of Marina Biotech to attract and/or maintain manufacturing, research, development and commercialization partners; (iii) the ability of Marina Biotech and/or a partner to successfully complete product research and development, including preclinical and clinical studies and commercialization; (iv) the ability of Marina Biotech and/or a partner to obtain required governmental approvals; and (v) the ability of Marina Biotech and/or a partner to develop and commercialize products that can compete favorably with those of competitors. Additional factors that could cause actual results to differ materially from those projected or suggested in any forward-looking statements are contained in Marina Biotech's most recent periodic reports on Form 10-K and Form 10-Q that are filed with the Securities and Exchange Commission. Marina Biotech assumes no obligation to update and supplement forward-looking statements because of subsequent events.

Contact Information

  • Contacts:
    Marina Biotech, Inc.
    Mark Bales, Ph.D., J.D.
    IP Counsel
    (425) 908-3634
    Email Contact